<DOC>
	<DOCNO>NCT00014430</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness vinorelbine plus trastuzumab treating patient refractory metastatic breast cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Trastuzumab Treating Patients With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose vinorelbine combination trastuzumab ( Herceptin ) patient HER-2/neu overexpressing unresectable metastatic non-small cell lung cancer ( close accrual 4/16/01 ) refractory locally advance metastatic breast cancer . - Determine pharmacokinetic pharmacodynamic profile regimen patient population . - Determine objective response rate patient treat regimen . OUTLINE : This dose-escalation study vinorelbine . Patients receive vinorelbine IV 5-10 minute day 1 8 , trastuzumab ( Herceptin ) IV 30-90 minute day 8 15 course 1 day 1 , 8 , 15 subsequent course . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3 6 patient receive escalate dos vinorelbine maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 30-35 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable metastatic nonsmall cell lung cancer Stage IIIB IV ( close accrual 4/16/01 ) OR Histologically confirm locally advanced breast cancer progress firstline chemotherapy metastatic breast cancer HER2/neu overexpression ( 1+ 3+ ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) ALT great 3 time ULN Renal : Creatinine great 2 time ULN Cardiovascular : No prior concurrent unstable angina No prior symptomatic congestive heart failure No myocardial infarction within past 6 month LVEF least 45 % echocardiogram MUGA receive prior anthracycline anthrapyrazole therapy Other : No prior hypersensitivity trastuzumab , Chinese hamster ovary cell protein , component product No medical illness would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior trastuzumab ( Herceptin ) Chemotherapy : See Disease Characteristics No prior vinorelbine Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
</DOC>